Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation

K. E. Thummel, D. D. Shen, T. D. Podoll, K. L. Kunze, W. F. Trager, C. E. Bacchi, C. L. Marsh, John McVicar, D. M. Barr, J. D. Perkins, R. L. Carithers

Research output: Contribution to journalArticle

217 Citations (Scopus)

Abstract

Immunosuppression therapy with cyclosporine is often hampered by significant interindividual variability in the metabolic clearance of the drug. It has been suggested that much of the variability in cyclosporine clearance is due to differences in the cytochrome P450 3A4 (CYP3A4) content in the liver and intestinal mucosa. A study was conducted in liver transplant recipients to characterize hepatic CYP3A4 variability during the first 10 days after surgery. The formation of 1'-hydroxymidazolam (1'-OH MDZ) was followed in the plasma after i.v. midazolam (MDZ) administration to 21 multiple-organ donors and to recipients of 10 of the 21 donor livers. Liver biopsy tissue was obtained from donors and recipients after the in vivo pharmacokinetic test. For liver donors, the plasma 1'-OH MDZ/MDZ concentration ratio 30 min after the i.v. MDZ dose was well correlated with the hepatic CYP3A4 content (r = .87, P < .001). Much of the variability in the two parameters was attributed to the administration of enzyme-inducing drugs before organ procurement. The mean hepatic CYP3A4 content and plasma 1'-OH MDZ/MDZ concentration ratio in six inducer-treated donors was 4.7-fold and 2.3-fold higher than the respective mean value for all other donors. The hepatic CYP3A4 content and plasma 1'-OH MDZ/MDZ ratio for liver recipients, studied on postoperative day 10, was negatively correlated with the respective parameter measured in donors on day 0 (r = -0.60 for CYP3A4 and r = -0.79 for 1'-OH MDZ/MDZ; P < .05 and P < .01). The dynamic changes in hepatic CYP3A4 expression during the perioperative period, some of which appear to be due to the effect of enzyme-inducing drugs, help explain the difficulties often encountered in the achievement and maintenance of therapeutic cyclosporine blood levels after liver transplantation.

Original languageEnglish (US)
Pages (from-to)557-566
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume271
Issue number1
StatePublished - 1994
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP3A
Midazolam
Liver Transplantation
Liver
Tissue Donors
Cyclosporine
Pharmaceutical Preparations
Perioperative Period
Tissue and Organ Procurement
Enzymes
Intestinal Mucosa
Ambulatory Surgical Procedures
Immunosuppression
Pharmacokinetics
Maintenance

ASJC Scopus subject areas

  • Pharmacology

Cite this

Use of midazolam as a human cytochrome P450 3A probe : II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. / Thummel, K. E.; Shen, D. D.; Podoll, T. D.; Kunze, K. L.; Trager, W. F.; Bacchi, C. E.; Marsh, C. L.; McVicar, John; Barr, D. M.; Perkins, J. D.; Carithers, R. L.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 271, No. 1, 1994, p. 557-566.

Research output: Contribution to journalArticle

Thummel, KE, Shen, DD, Podoll, TD, Kunze, KL, Trager, WF, Bacchi, CE, Marsh, CL, McVicar, J, Barr, DM, Perkins, JD & Carithers, RL 1994, 'Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation', Journal of Pharmacology and Experimental Therapeutics, vol. 271, no. 1, pp. 557-566.
Thummel, K. E. ; Shen, D. D. ; Podoll, T. D. ; Kunze, K. L. ; Trager, W. F. ; Bacchi, C. E. ; Marsh, C. L. ; McVicar, John ; Barr, D. M. ; Perkins, J. D. ; Carithers, R. L. / Use of midazolam as a human cytochrome P450 3A probe : II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. In: Journal of Pharmacology and Experimental Therapeutics. 1994 ; Vol. 271, No. 1. pp. 557-566.
@article{c71584f3e40c42c2a3c7860a9549c09d,
title = "Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation",
abstract = "Immunosuppression therapy with cyclosporine is often hampered by significant interindividual variability in the metabolic clearance of the drug. It has been suggested that much of the variability in cyclosporine clearance is due to differences in the cytochrome P450 3A4 (CYP3A4) content in the liver and intestinal mucosa. A study was conducted in liver transplant recipients to characterize hepatic CYP3A4 variability during the first 10 days after surgery. The formation of 1'-hydroxymidazolam (1'-OH MDZ) was followed in the plasma after i.v. midazolam (MDZ) administration to 21 multiple-organ donors and to recipients of 10 of the 21 donor livers. Liver biopsy tissue was obtained from donors and recipients after the in vivo pharmacokinetic test. For liver donors, the plasma 1'-OH MDZ/MDZ concentration ratio 30 min after the i.v. MDZ dose was well correlated with the hepatic CYP3A4 content (r = .87, P < .001). Much of the variability in the two parameters was attributed to the administration of enzyme-inducing drugs before organ procurement. The mean hepatic CYP3A4 content and plasma 1'-OH MDZ/MDZ concentration ratio in six inducer-treated donors was 4.7-fold and 2.3-fold higher than the respective mean value for all other donors. The hepatic CYP3A4 content and plasma 1'-OH MDZ/MDZ ratio for liver recipients, studied on postoperative day 10, was negatively correlated with the respective parameter measured in donors on day 0 (r = -0.60 for CYP3A4 and r = -0.79 for 1'-OH MDZ/MDZ; P < .05 and P < .01). The dynamic changes in hepatic CYP3A4 expression during the perioperative period, some of which appear to be due to the effect of enzyme-inducing drugs, help explain the difficulties often encountered in the achievement and maintenance of therapeutic cyclosporine blood levels after liver transplantation.",
author = "Thummel, {K. E.} and Shen, {D. D.} and Podoll, {T. D.} and Kunze, {K. L.} and Trager, {W. F.} and Bacchi, {C. E.} and Marsh, {C. L.} and John McVicar and Barr, {D. M.} and Perkins, {J. D.} and Carithers, {R. L.}",
year = "1994",
language = "English (US)",
volume = "271",
pages = "557--566",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Use of midazolam as a human cytochrome P450 3A probe

T2 - II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation

AU - Thummel, K. E.

AU - Shen, D. D.

AU - Podoll, T. D.

AU - Kunze, K. L.

AU - Trager, W. F.

AU - Bacchi, C. E.

AU - Marsh, C. L.

AU - McVicar, John

AU - Barr, D. M.

AU - Perkins, J. D.

AU - Carithers, R. L.

PY - 1994

Y1 - 1994

N2 - Immunosuppression therapy with cyclosporine is often hampered by significant interindividual variability in the metabolic clearance of the drug. It has been suggested that much of the variability in cyclosporine clearance is due to differences in the cytochrome P450 3A4 (CYP3A4) content in the liver and intestinal mucosa. A study was conducted in liver transplant recipients to characterize hepatic CYP3A4 variability during the first 10 days after surgery. The formation of 1'-hydroxymidazolam (1'-OH MDZ) was followed in the plasma after i.v. midazolam (MDZ) administration to 21 multiple-organ donors and to recipients of 10 of the 21 donor livers. Liver biopsy tissue was obtained from donors and recipients after the in vivo pharmacokinetic test. For liver donors, the plasma 1'-OH MDZ/MDZ concentration ratio 30 min after the i.v. MDZ dose was well correlated with the hepatic CYP3A4 content (r = .87, P < .001). Much of the variability in the two parameters was attributed to the administration of enzyme-inducing drugs before organ procurement. The mean hepatic CYP3A4 content and plasma 1'-OH MDZ/MDZ concentration ratio in six inducer-treated donors was 4.7-fold and 2.3-fold higher than the respective mean value for all other donors. The hepatic CYP3A4 content and plasma 1'-OH MDZ/MDZ ratio for liver recipients, studied on postoperative day 10, was negatively correlated with the respective parameter measured in donors on day 0 (r = -0.60 for CYP3A4 and r = -0.79 for 1'-OH MDZ/MDZ; P < .05 and P < .01). The dynamic changes in hepatic CYP3A4 expression during the perioperative period, some of which appear to be due to the effect of enzyme-inducing drugs, help explain the difficulties often encountered in the achievement and maintenance of therapeutic cyclosporine blood levels after liver transplantation.

AB - Immunosuppression therapy with cyclosporine is often hampered by significant interindividual variability in the metabolic clearance of the drug. It has been suggested that much of the variability in cyclosporine clearance is due to differences in the cytochrome P450 3A4 (CYP3A4) content in the liver and intestinal mucosa. A study was conducted in liver transplant recipients to characterize hepatic CYP3A4 variability during the first 10 days after surgery. The formation of 1'-hydroxymidazolam (1'-OH MDZ) was followed in the plasma after i.v. midazolam (MDZ) administration to 21 multiple-organ donors and to recipients of 10 of the 21 donor livers. Liver biopsy tissue was obtained from donors and recipients after the in vivo pharmacokinetic test. For liver donors, the plasma 1'-OH MDZ/MDZ concentration ratio 30 min after the i.v. MDZ dose was well correlated with the hepatic CYP3A4 content (r = .87, P < .001). Much of the variability in the two parameters was attributed to the administration of enzyme-inducing drugs before organ procurement. The mean hepatic CYP3A4 content and plasma 1'-OH MDZ/MDZ concentration ratio in six inducer-treated donors was 4.7-fold and 2.3-fold higher than the respective mean value for all other donors. The hepatic CYP3A4 content and plasma 1'-OH MDZ/MDZ ratio for liver recipients, studied on postoperative day 10, was negatively correlated with the respective parameter measured in donors on day 0 (r = -0.60 for CYP3A4 and r = -0.79 for 1'-OH MDZ/MDZ; P < .05 and P < .01). The dynamic changes in hepatic CYP3A4 expression during the perioperative period, some of which appear to be due to the effect of enzyme-inducing drugs, help explain the difficulties often encountered in the achievement and maintenance of therapeutic cyclosporine blood levels after liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0027985506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027985506&partnerID=8YFLogxK

M3 - Article

C2 - 7965756

AN - SCOPUS:0027985506

VL - 271

SP - 557

EP - 566

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -